A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

Myasthenia Gravis Clinical Trial

Official title:

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03863080
• Other study ID #: RVT-1401-2002
• Status: Completed
• Phase: Phase 2
• Start date: May 21, 2019
• Est. completion date: December 21, 2020

Study information

• Verified date: November 2023
• Source: Immunovant Sciences GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compared to placebo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: December 21, 2020
• Est. primary completion date: October 7, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female = 18 years of age.

2. Myasthenia Gravis Foundation of America (MGFA) Class II-IVa and likely not in need of a respirator for the duration of the study as judged by the Investigator.

3. QMG score =12 at Screening and Baseline.

Other, more specific inclusion criteria are defined in the protocol.

Exclusion Criteria:

1. Use of rituximab, belimumab, eculizumab or any monoclonal antibody for immunomodulation within 6 months prior to first dosing.

2. Immunoglobulins given by SC, IV (IVIG), or intramuscular route, or plasmapheresis/plasma exchange (PE) within 4 weeks before Screening.

3. Thymectomy performed < 12 months prior to screening.

4. Total IgG level <6 g/L (at screening).

5. Absolute neutrophil count <1500 cells/mm3(at screening).

Other, more specific exclusion criteria are defined in the protocol

Related Conditions & MeSH terms

• Muscle Weakness
• Myasthenia Gravis

Intervention

Drug:
• RVT-1401
Subcutaneous administration of RVT-1401
• Placebo
Subcutaneous administration of Placebo

Locations

Country	Name	City	State
Canada	University of Alberta Hospitals - Division of Pulmonary Medicine	Edmonton	Alberta
Canada	London Health Sciences Centre	London	Ontario
Canada	Montreal Neurological Institute and Hospital	Montreal	Quebec
Canada	Ottawa Hospital Research Institute	Ottawa	Ontario
Canada	University Health Network Toronto General Hospital	Toronto	Ontario
United States	Dent Institute	Amherst	New York
United States	Rare Disease Research	Atlanta	Georgia
United States	University of Buffalo	Buffalo	New York
United States	The Neurology Center of Southern California	Carlsbad	California
United States	CSNA	Colorado Springs	Colorado
United States	UTSW James W. Aston Ambulatory Care Center - Neurology Clinic	Dallas	Texas
United States	University of Minnesota - Department of Neurology	Minneapolis	Minnesota
United States	IMC/Diagnostic and Medical Clinic	Mobile	Alabama
United States	Yale School of Medicine Department of Neurology	New Haven	Connecticut
United States	Hospital for Special Surgery	New York	New York
United States	UC Irvine - MDA ALS and Neuromuscular Center	Orange	California
United States	Neurological Services of Orlando	Orlando	Florida
United States	Care Access Research	Pasadena	California
United States	Phoenix Neurological Associates	Phoenix	Arizona
United States	Allegheny Neurological Associates	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Immunovant Sciences GmbH

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Double-Blind Treatment Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.	Up to Week 18
Primary	Open-Label Extension Period: Number of Participants Reporting AEs and SAEs	An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as those AEs that started or worsened in severity after the initiation of study drug administration. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.	Up to Week 18
Primary	Double-Blind Treatment Period: Number of Participants With Clinically Significant Changes in Vital Signs	Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse rate and temperature were measured after resting for at least 5 minutes in a semi-supine position.	Up to Week 7
Primary	Open-label Extension Period: Number of Participants With Clinically Significant Changes in Vital Signs	Vital signs including SBP, DBP, pulse rate and temperature were measured after resting for at least 5 minutes in a semi-supine position.	Up to Week 18
Primary	Double-blind Treatment Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters	Clinical laboratory parameters included clinical chemistry, hematology and urinalysis.	Up to Week 7
Primary	Open-label Extension Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters	Clinical laboratory parameters included clinical chemistry, hematology and urinalysis.	Up to Week 18
Primary	Double-Blind Treatment Period: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG)	Twelve-lead ECG was performed after 5 minutes of rest in the supine position.	Up to Week 7
Primary	Open-label Extension Period: Number of Participants With Clinically Significant Changes in ECG	Twelve-lead ECG was performed after 5 minutes of rest in the supine position.	Up to Week 18
Primary	Double-blind Treatment Period: Percent Change From Baseline in Levels of Total Immunoglobulin G (IgG)	Serum samples were collected for the analysis of total immunoglobulin G. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7) minus the Baseline value, divided by the Baseline value x 100.	Baseline (Day 1) and Up to Week 7
Primary	Double-blind Treatment Period: Percent Change From Baseline in IgG Subclasses 1, 2, 3 and 4	Serum samples were collected for the analysis of IgG 1, 2, 3 and 4 levels. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7) minus the Baseline value, divided by the Baseline value x 100.	Baseline (Day 1) and Up to Week 7
Primary	Double-Blind Treatment Period: Percent Change From Baseline in Anti-acetylcholine Receptor Immunoglobulin G (Anti-AChR-IgG) at Week 7	Serum samples were collected for the analysis of Anti-AChR-IgG. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7) minus the Baseline value, divided by the Baseline value x 100.	Baseline (Day 1) and Week 7
Secondary	Double-Blind Treatment Period: Area Under the Concentration-time Curve From Time 0 to 168 Hours (AUC0-168h) of RVT-1401	Blood samples were collected for the analysis of Pharmacokinetic parameter AUC (0-168h).	Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8
Secondary	Open-label Extension Period: AUC0-168h of RVT-1401	Pharmacokinetic parameters were not estimated because the sparse PK sampling schedule did not allow for accurate estimates of these parameters.	Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8, Week 9, Week 12 and Week 14
Secondary	Double-Blind Treatment Period: Maximum Concentration (Cmax) of RVT-1401	Blood samples were collected for the analysis of Pharmacokinetic parameter Cmax.	Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8
Secondary	Open-label Extension Period: Cmax of RVT-1401	Blood samples were collected for the analysis of Pharmacokinetic parameter Cmax.	Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8, Week 9, Week 12 and Week 14
Secondary	Double-Blind Treatment Period: Trough Concentrations (Ctrough) of RVT-1401	Blood samples were planned to be collected at indicated time points to measure the concentration of RVT-1401 pre-dose (Ctrough) as an assessment of the pharmacokinetic RVT-1401.	Pre-dose
Secondary	Open-label Extension Period: Ctrough of RVT-1401	Blood samples were planned to be collected at indicated time points to measure the concentration of RVT-1401 pre-dose (Ctrough) as an assessment of the pharmacokinetic RVT-1401.	Pre-dose
Secondary	Double-blind Treatment Period: Change From Baseline in the Quantitative Myasthenia Gravis Score (QMG) Score	The QMG score is a physician-reported outcome measure was used to assess MG disease severity and pattern of deficits based on quantitative testing of affected muscle groups. The scale comprised of 13 test items that were graded on a scale of 0 (no myasthenic findings) to 3 (maximal myasthenic deficits). The total sum across all 13 items represents the QMG score. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.	Baseline (Day 1) and at Week 2, Week 3, Week 4, Week 5, Week 6 (Day 36) and Week 7
Secondary	Double-Blind Treatment Period: Percentage of Participants With an Improvement/ Response on the QMG Score From Baseline	The response is defined as improvement from Baseline on the QMG score by => 3 points. The QMG score is a physician-reported outcome measure was used to assess MG disease severity and pattern of deficits based on quantitative testing of affected muscle groups. The scale comprised of 13 test items that were graded on a scale of 0 (no myasthenic findings) to 3 (maximal myasthenic deficits). The total sum across all 13 items represents the QMG score. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.	Baseline (Day 1) to Week 7
Secondary	Double-Blind Treatment Period: Change From Baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) Score	The MG-ADL is an 8-item, participant-reported outcome measure that assessed Myasthenia Gravis symptoms and their effects on activities of daily living, with each response graded from 0 (normal) to 3 (most severe). The MG-ADL score was calculated by totaling the rating for each of the 8 items. Total MG-ADL scores range from 0 to 24 with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.	Baseline (Day 1) and at Week 2, Week 3, Week 4, Week 5, Week 6 (Day 36), Week 7
Secondary	Double-Blind Treatment Period: Percentage of Participants With an Improvement/ Response on the MG-ADL Score	The response was defined as improvement (decrease) from Baseline on the MG-ADL score by => 2 points. The MG-ADL is an 8-item, participant-reported outcome measure that assessed Myasthenia Gravis symptoms and their effects on activities of daily living, with each response graded from 0 (normal) to 3 (most severe). The MG-ADL score was calculated by totaling the rating for each of the 8 items. Total MG-ADL scores range from 0 to 24 with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug.	Baseline (Day 1) to Week 7
Secondary	Double-Blind Treatment Period: Change From Baseline in the Myasthenia Gravis Composite Score (MGC) Score	The MGC was developed by selecting the best performing items from 3 commonly used Myasthenia Gravis specific scales (QMG, Myasthenia Gravis manual muscle test, and MG-ADL) and is comprised of 10 functional domains: 3 ocular, 3 bulbar, 1 respiratory, 1 neck, and 2 limb items. The total score ranges from 0 (no myasthenic findings) to 50 (maximal myasthenic deficits). The scale measures symptoms and signs of MG in these domains incorporating both physician and participant-reported test items. Higher scores correlate with clinical worsening of the disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.	Baseline (Day 1) and at Week 2, Week 3, Week 4, Week 5, Week 6 (Day 36), Week 7
Secondary	Double-Blind Treatment Period: Percentage of Participants With an Improvement on the MGC Score	The response was defined as improvement (decrease) from Baseline on the MGC score by => 3 points. The MGC was developed by selecting the best performing items from 3 commonly used Myasthenia Gravis specific scales (QMG, Myasthenia Gravis manual muscle test, and MG-ADL) and is comprised of 10 functional domains: 3 ocular, 3 bulbar, 1 respiratory, 1 neck, and 2 limb items. The total score ranges from 0 (no myasthenic findings) to 50 (maximal myasthenic deficits). The scale measures symptoms and signs of MG in these domains incorporating both physician and participant-reported test items. Higher scores correlate with clinical worsening of the disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug.	Baseline (Day 1) to Week 7
Secondary	Double-Blind Treatment Period: Change From Baseline in the Myasthenia Gravis Quality of Life 15 Revised Score (MG-QOL 15r) Score	The MG-QOL15r is a participant-reported questionnaire designed to assess how a participant's Myasthenia Gravis affects different aspects related to their quality of life. The scale includes 15 items that are graded on a scale of 0 to2; the total across is the sum of all 15 items and represents the MG-QOL15r score. The range of the MG-QOL15r score is 0 - 30. Higher scores indicate worse outcomes. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.	Baseline (Day 1) and at Week 4 and Week 7
Secondary	Double-Blind Treatment Period: Number of Participants Reporting Confirmed Positive Anti-RVT-1401 Antibodies	The serum levels of anti-RVT-1401 antibodies were determined. All samples that were potentially positive were analyzed with the confirmation assay where presence of anti-RVT-1401 was confirmed; the therapeutic antibody was used to compete with the analytical responses of anti-drug antibody (ADA) to assess specificity of screened positive samples.	Up to Week 7
Secondary	Open-Label Extension Period: Number of Participants Reporting Confirmed Positive Anti-RVT-1401 Antibodies	The serum levels of anti-RVT-1401 antibodies were determined. All samples that were potentially positive were analyzed with the confirmation assay where presence of anti-RVT-1401 was confirmed; the therapeutic antibody was used to compete with the analytical responses of ADA to assess specificity of screened positive samples.	Up to Week 18